CA3010609A1 - Treatments and prevention of opioid neonatal abstinence syndrome - Google Patents

Treatments and prevention of opioid neonatal abstinence syndrome Download PDF

Info

Publication number
CA3010609A1
CA3010609A1 CA3010609A CA3010609A CA3010609A1 CA 3010609 A1 CA3010609 A1 CA 3010609A1 CA 3010609 A CA3010609 A CA 3010609A CA 3010609 A CA3010609 A CA 3010609A CA 3010609 A1 CA3010609 A1 CA 3010609A1
Authority
CA
Canada
Prior art keywords
opioid
fetal
treatments
prevention
pregnant subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3010609A
Other languages
English (en)
French (fr)
Inventor
Wolfgang Sadee
John OBERDICK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of CA3010609A1 publication Critical patent/CA3010609A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
CA3010609A 2016-01-08 2017-01-06 Treatments and prevention of opioid neonatal abstinence syndrome Pending CA3010609A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662276691P 2016-01-08 2016-01-08
US62/276,691 2016-01-08
PCT/US2017/012452 WO2017120417A1 (en) 2016-01-08 2017-01-06 Treatments and prevention of opioid neonatal abstinence syndrome

Publications (1)

Publication Number Publication Date
CA3010609A1 true CA3010609A1 (en) 2017-07-13

Family

ID=59274434

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3010609A Pending CA3010609A1 (en) 2016-01-08 2017-01-06 Treatments and prevention of opioid neonatal abstinence syndrome

Country Status (8)

Country Link
US (3) US10925870B2 (https=)
EP (1) EP3400066B1 (https=)
JP (1) JP7061568B2 (https=)
CN (1) CN108778423A (https=)
AU (1) AU2017206041B2 (https=)
CA (1) CA3010609A1 (https=)
DK (1) DK3400066T3 (https=)
WO (1) WO2017120417A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019199704A1 (en) * 2018-04-09 2019-10-17 Katana Pharmaceuticals, Inc. Oxytocin compositions and methods of use
CN113573711A (zh) * 2019-01-04 2021-10-29 伊瑟治疗公司 治疗药物或酒精依赖性的方法
US10653690B1 (en) * 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
CN117915916A (zh) * 2021-07-06 2024-04-19 伊瑟治疗公司 低剂量纳曲醇和其用途
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049375A1 (en) * 2000-03-15 2001-12-06 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
SI1646328T1 (sl) * 2003-07-25 2008-02-29 Euro Celtique Sa Zdravljenje pri odvajanju od odvisnosti
KR20070086334A (ko) * 2004-11-16 2007-08-27 리머릭 뉴로사이언스즈, 인크. 통증을 치료하기 위한 방법 및 조성물
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
EP2214672B1 (en) 2007-10-18 2012-10-17 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
WO2009079489A1 (en) * 2007-12-17 2009-06-25 The Ohio State University Research Foundation Methods for screening of opioid receptor neutral antagonists and inverse agonists and uses thereof
US9226918B2 (en) * 2008-12-04 2016-01-05 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms

Also Published As

Publication number Publication date
JP2019501194A (ja) 2019-01-17
US20250177379A1 (en) 2025-06-05
US12161641B2 (en) 2024-12-10
EP3400066A1 (en) 2018-11-14
EP3400066A4 (en) 2019-06-26
AU2017206041B2 (en) 2022-07-28
AU2017206041A1 (en) 2018-07-26
US10925870B2 (en) 2021-02-23
WO2017120417A1 (en) 2017-07-13
EP3400066B1 (en) 2021-07-28
DK3400066T3 (da) 2021-10-18
NZ744112A (en) 2025-05-30
US20190015406A1 (en) 2019-01-17
CN108778423A (zh) 2018-11-09
US20210205296A1 (en) 2021-07-08
JP7061568B2 (ja) 2022-04-28

Similar Documents

Publication Publication Date Title
CA3010609A1 (en) Treatments and prevention of opioid neonatal abstinence syndrome
PH12018501969A1 (en) Pharmaceutical composition comprising empagliflozin and uses thereof
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
MY192033A (en) Method of dosing and use of soft anticholinergic esters
ZA202000028B (en) Use of vibegron to treat overactive bladder
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
HK1255481A1 (zh) 用於治疗hcv的方法
JP2016520114A5 (https=)
HK1222585A1 (zh) 用於提供疼痛减轻和麻醉的二氢埃托啡
WO2014107685A3 (en) Compositions and methods for using huperzine and analogs thereof
WO2017189906A8 (en) Immune-based treatment of kras-variant cancer patients
TN2011000366A1 (en) Use of deferiprone for treatment and prevention of iron-related eye dosorders
WO2020025657A9 (en) Composition for use in the prevention and/or treatment of the genitourinary mucosa
RU2014152196A (ru) Способ улучшения функции печени
NZ744112B2 (en) Treatments and prevention of opioid neonatal abstinence syndrome
MX2018013474A (es) Acidos carboxilicos para aplicacion en la primera infancia.
WO2013172923A8 (en) Uses of antagonists of hyaluronan signaling
Speich Subdural haematoma: 2 case reports
Botros Enoxaparin sodium
Elalfy Agranulocytosis and neutropenia: 4 case reports
Tsubata Blood pressure changes and bradycardia: case report
Palacios-Zabalza Acenocoumarol/levofloxacin
Morales Bradycardia and hypotension: case report
Kachalia et al. C42 CLINICAL TRIALS: Analysis Of Safety And Efficacy Of Dexmedetomidine As Adjunctive Therapy For Alcohol Withdrawal In Intensive Care Unit

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211221

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241007

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241227

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241227

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241230

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250513

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250513

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250819

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250819

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20251201

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260102

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260102

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260309

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260309